Choosing the Right Drug Name

Webinar Details

whenWhen?  Tuesday, July 22, 2014
whereWhere? Your Office
whenTime? 1:30 p.m. - 3:00 p.m. EDT


Webinar plus Audio CD/Transcript $487
Webinar only $287
24/7 Encore plus CD/Transcript $487
24/7 Encore Presentation $287
Audio CD/Transcript $287

Choosing the Right Drug Name
How to Increase Your Chances for Approval

The FDA rejects 40% of the drug names presented to it each year. 

Not surprisingly, the drug industry has long criticized the agency about its name approval process.

So, in May 2014, the FDA released a draft guidance that covers the selection and approval process for proposed names of both prescription and nonprescription human drugs and biologics. In the guidance, the FDA describes its own review processes in detail and lays out 4 steps your company should follow in choosing a drug name. 

To address this issue, FDAnews has teamed with drug-naming expert Dr. Susan Proulx to present a 90-minute webinar that will look closely at the draft guidance and its recommended 4-step process. Dr. Proulx will provide ideas on how to win the FDA’s approval for your suggested drug name.

BONUS HANDOUT: Attendees will receive their own copy of a chart that compares drug name approval regulations in the US and Canada.

And you'll learn more about the following:

  • How the new guidance will impact on drug trademark development (in time, money, and the differences from country to country that affect processing for a global mark)
  • Pros and cons of relying on computerized searching to identify similarity in proposed names
  • Simulation testing and how it may provide useful insight into how a proposed proprietary name might perform in real world conditions
  • The need for expert analysis before you decide what trademark to choose

Choosing the Right Drug Name: How to Increase Your Chances for Approval is sure to be a presentation you won't want to miss.

Register now for this can't-miss July 22 event. It's a very small investment in time and money … that might save your company millions.